These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 20167811)

  • 1. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
    de Groot JF; Fuller G; Kumar AJ; Piao Y; Eterovic K; Ji Y; Conrad CA
    Neuro Oncol; 2010 Mar; 12(3):233-42. PubMed ID: 20167811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
    Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
    J Neurooncol; 2011 Jun; 103(2):353-60. PubMed ID: 20848300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
    Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
    Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
    Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI.
    Lescher S; Jurcoane A; Veit A; Bähr O; Deichmann R; Hattingen E
    Neuroradiology; 2015 Jan; 57(1):11-20. PubMed ID: 25287076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
    Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
    Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time course of imaging changes of GBM during extended bevacizumab treatment.
    Ananthnarayan S; Bahng J; Roring J; Nghiemphu P; Lai A; Cloughesy T; Pope WB
    J Neurooncol; 2008 Jul; 88(3):339-47. PubMed ID: 18389177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
    Furuta T; Nakada M; Misaki K; Sato Y; Hayashi Y; Nakanuma Y; Hamada J
    Brain Tumor Pathol; 2014 Jan; 31(1):32-9. PubMed ID: 23504126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
    Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
    Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.
    Hattingen E; Jurcoane A; Bähr O; Rieger J; Magerkurth J; Anti S; Steinbach JP; Pilatus U
    Neuro Oncol; 2011 Dec; 13(12):1349-63. PubMed ID: 21890539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.
    Keunen O; Johansson M; Oudin A; Sanzey M; Rahim SA; Fack F; Thorsen F; Taxt T; Bartos M; Jirik R; Miletic H; Wang J; Stieber D; Stuhr L; Moen I; Rygh CB; Bjerkvig R; Niclou SP
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3749-54. PubMed ID: 21321221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
    Kickingereder P; Wiestler B; Graf M; Heiland S; Schlemmer HP; Wick W; Wick A; Bendszus M; Radbruch A
    J Neurooncol; 2015 Jan; 121(2):373-80. PubMed ID: 25359396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
    Wick W; Wick A; Weiler M; Weller M
    Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.